Home › Encyclopedia › Tabimorelin: Research Status and Available Data
Research / Unapproved

Tabimorelin: Research Status and Available Data

Molecular formulaC32H40N4O3
Molecular weight528.7 g/mol
Registered trials0
PubChem CID9810101

What tabimorelin is

Tabimorelin is a synthetic compound identified in chemical databases under PubChem CID 9810101, with a molecular formula of C32H40N4O3. It has no approved drug label from any regulatory agency, and no brand name exists for it. Tabimorelin is classified as an unapproved research compound, meaning it has not been evaluated or authorized by the FDA for any use in humans.

Trial footprint

There are no registered clinical trials for tabimorelin in the data reviewed. No trial records, phases, or enrollment details are available to describe its study history or current research activity.

FAQ

Is tabimorelin FDA approved?
No. Tabimorelin has no FDA-approved label and is classified as an unapproved research compound. It is not authorized for any medical use.
What is tabimorelin's chemical identity?
Tabimorelin has the molecular formula C32H40N4O3 and a molecular weight of about 528.7. It is catalogued in PubChem under CID 9810101.
Are there any clinical trials studying tabimorelin?
The available data shows no registered clinical trials for tabimorelin. There is no public trial record describing its study status or history.
What side effects are associated with tabimorelin?
No side effect or adverse event report data is available for tabimorelin in the sources reviewed. This means no pattern of reported reactions can be summarized at this time.
Does tabimorelin have a brand name?
No. Because tabimorelin lacks an approved label, it has not been assigned any brand name by regulatory authorities.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: PubChem

Updated 2026-09-19